MA59554B1 - Composé de pipéridine substitué et son application - Google Patents

Composé de pipéridine substitué et son application

Info

Publication number
MA59554B1
MA59554B1 MA59554A MA59554A MA59554B1 MA 59554 B1 MA59554 B1 MA 59554B1 MA 59554 A MA59554 A MA 59554A MA 59554 A MA59554 A MA 59554A MA 59554 B1 MA59554 B1 MA 59554B1
Authority
MA
Morocco
Prior art keywords
compound
application
substituted piperidin
piperidin
substituted
Prior art date
Application number
MA59554A
Other languages
English (en)
Inventor
Yu Yoshida
Yoichi Kita
Makoto Kotake
Keiichi Sorimachi
Toshiyuki Ohfusa
Takafumi Motoki
Taro Asaba
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of MA59554B1 publication Critical patent/MA59554B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pain & Pain Management (AREA)

Abstract

Sont fournis les composés représentés par les formules suivantes (I), (II), (III) et (IV) ayant une activité d'activation du récepteur de type 2 de l'orexine, ou leurs sels pharmaceutiquement acceptables
MA59554A 2020-07-17 2021-07-15 Composé de pipéridine substitué et son application MA59554B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020122864 2020-07-17
EP21842047.9A EP4151277B1 (fr) 2020-07-17 2021-07-15 Composé de pipéridine substitué et son application
PCT/JP2021/026649 WO2022014680A1 (fr) 2020-07-17 2021-07-15 Composé de pipéridine substitué et son application

Publications (1)

Publication Number Publication Date
MA59554B1 true MA59554B1 (fr) 2026-04-30

Family

ID=79291962

Family Applications (1)

Application Number Title Priority Date Filing Date
MA59554A MA59554B1 (fr) 2020-07-17 2021-07-15 Composé de pipéridine substitué et son application

Country Status (28)

Country Link
US (1) US11479552B2 (fr)
EP (1) EP4151277B1 (fr)
JP (1) JP7190612B2 (fr)
KR (1) KR20230040953A (fr)
CN (3) CN119258067A (fr)
AR (1) AR122973A1 (fr)
AU (1) AU2021308053A1 (fr)
BR (1) BR112022026161A2 (fr)
CA (1) CA3187835A1 (fr)
CL (1) CL2022003666A1 (fr)
CO (1) CO2022018446A2 (fr)
DK (1) DK4151277T3 (fr)
FI (1) FI4151277T3 (fr)
HR (1) HRP20260428T1 (fr)
IL (1) IL299125B2 (fr)
JO (1) JOP20220345A1 (fr)
LT (1) LT4151277T (fr)
MA (1) MA59554B1 (fr)
MX (1) MX2022016388A (fr)
PE (1) PE20231103A1 (fr)
PH (1) PH12022553488A1 (fr)
PT (1) PT4151277T (fr)
RS (1) RS67943B1 (fr)
SM (1) SMT202600159T1 (fr)
TW (1) TWI888599B (fr)
UA (1) UA129636C2 (fr)
WO (1) WO2022014680A1 (fr)
ZA (1) ZA202213562B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020394444B2 (en) 2019-11-25 2025-05-29 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
AU2023206823A1 (en) * 2022-01-14 2024-07-11 Eisai R&D Management Co., Ltd. Crystal of substituted piperidine compound, salts of substituted piperidine compound, and crystals thereof
JP7591592B2 (ja) * 2022-01-14 2024-11-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 置換ピペリジン化合物を含有する医薬
CN119968355A (zh) * 2022-10-07 2025-05-09 橘生药品工业株式会社 环戊烷化合物
TW202432109A (zh) * 2022-10-31 2024-08-16 日商武田藥品工業股份有限公司 食慾素2型受體促效劑之給藥
TW202430169A (zh) 2022-12-16 2024-08-01 日商第一三共股份有限公司 2-氮雜雙環[3.1.1]庚烷化合物
WO2024246867A1 (fr) 2023-06-02 2024-12-05 Takeda Pharmaceutical Company Limited Utilisation d'un agoniste du récepteur de l'orexine 2 pour améliorer la fonction respiratoire pendant le sommeil
WO2025124698A1 (fr) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Dérivés d'arylsulfone et de sulfanone utilisés en tant que modulateurs du récepteur de l'orexine
WO2025132542A1 (fr) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Agonistes macrocycliques de l'orexine
WO2025137359A1 (fr) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Procédés de dosage servant à identifier une maladie
WO2025229493A1 (fr) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosage d'agonistes du récepteur de l'orexine de type 2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG34208A1 (en) 1995-03-01 1996-12-06 Guy Andrew Vaz Blast and fragment resistant polyurethane boot sole for safety footwear
CA2220036A1 (fr) 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Recepteur de neuropeptides humain
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6159605A (en) 1997-02-18 2000-12-12 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Ink-jet recording sheet
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
KR100327888B1 (ko) 1999-07-14 2002-03-09 정숭렬 도로포장 파손촉진 시험장치의 무선제어 시스템
JP4765627B2 (ja) * 2003-09-22 2011-09-07 Msd株式会社 新規ピペリジン誘導体
CA2584838A1 (fr) 2004-10-20 2006-05-04 Neurosearch A/S Nouveaux derives aryle diazabicycliques et leur utilisation medicale
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途

Also Published As

Publication number Publication date
IL299125A (en) 2023-02-01
EP4151277A1 (fr) 2023-03-22
KR20230040953A (ko) 2023-03-23
JP7190612B2 (ja) 2022-12-15
CN115884971A (zh) 2023-03-31
CO2022018446A2 (es) 2023-03-07
MX2022016388A (es) 2023-01-30
DK4151277T3 (da) 2026-04-13
US11479552B2 (en) 2022-10-25
UA129636C2 (uk) 2025-06-18
HRP20260428T1 (hr) 2026-05-08
TW202542144A (zh) 2025-11-01
US20220017517A1 (en) 2022-01-20
RS67943B1 (sr) 2026-04-30
PH12022553488A1 (en) 2024-04-22
CN119258067A (zh) 2025-01-07
CL2022003666A1 (es) 2023-05-26
EP4151277A4 (fr) 2024-06-26
PE20231103A1 (es) 2023-07-19
TWI888599B (zh) 2025-07-01
EP4151277B1 (fr) 2026-01-28
AU2021308053A1 (en) 2023-02-02
TW202216705A (zh) 2022-05-01
IL299125B2 (en) 2026-03-01
IL299125B1 (en) 2025-11-01
ZA202213562B (en) 2023-10-25
BR112022026161A2 (pt) 2023-01-31
JOP20220345A1 (ar) 2022-12-21
AR122973A1 (es) 2022-10-19
PT4151277T (pt) 2026-04-06
WO2022014680A1 (fr) 2022-01-20
CA3187835A1 (fr) 2022-01-20
JPWO2022014680A1 (fr) 2022-01-20
CN119235864A (zh) 2025-01-03
SMT202600159T1 (it) 2026-05-12
CN115884971B (zh) 2024-11-05
FI4151277T3 (fi) 2026-03-27
LT4151277T (lt) 2026-04-10

Similar Documents

Publication Publication Date Title
JOP20220345A1 (ar) مركبات بيبريدين بها استبدال واستخدامها
MX2025004220A (es) Compuestos triciclicos y sus usos
PY2240956A (es) Nuevos Compuestos bicíclicos y sus usos
AR132340A1 (es) Compuestos tricíclicos para el tratamiento de cáncer
AR132294A1 (es) Inhibidores de kras
AR132295A1 (es) Inhibidores de kras
AR133985A1 (es) Inhibidores de kras
PA8556201A1 (es) Alquinos como inhibidores de metaloproteinasa de matriz
UY24409A1 (es) Inhibidores de la matriz metaloproteasa
JOP20240250A1 (ar) مركبات واستخداماتها
MX2022009043A (es) Compuestos de sulfonimidamida como moduladores de nlrp3.
BRPI0411414A (pt) derivados de quinolil amida como antagonistas de cdr-5
MX2023012971A (es) Agonistas del receptor de orexina y sus usos.
TN2011000252A1 (fr) Lactames servant d&#39;inhibiteurs de beta-secretase
EA200601076A1 (ru) Применение производных n-арилгидразина для борьбы с вредителями
MA41790B1 (fr) Dérivé de morphinane
JOP20250214A1 (ar) مشتقات هيدروكينازولين لعلاج مرض أو اضطراب
CO2023006912A2 (es) Nuevos derivados de indazol acetileno
ATE409177T1 (de) Synthetische multiple quaternäre ammoniumsalze
IL307274A (en) Substituted 1-aryl-1&#39;-heteroaryl compounds, substituted 1,1&#39;-biheteroaryl compounds, and methods using same
CR20240353A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
JOP20240119A1 (ar) مشتقات نافثيريدينون لمعالجة مرض أو اضطراب
BR112022009856A2 (pt) Compostos de 1,8-naftiridin-2-ona para o tratamento de doença autoimune
AR131023A1 (es) Compuesto, antagonista del receptor de endotelina a, antagonista del receptor de angiotensina ii de tipo 1 y composición farmacéutica
MX2024001265A (es) Compuestos inhibidores de serotonina 5-ht2b.